Mizuho Increases Doximity (NASDAQ:DOCS) Price Target to $65.00

Doximity (NASDAQ:DOCS) had its price objective boosted by Mizuho from $55.00 to $65.00 in a research note published on Monday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other analysts also recently weighed in on the stock. Needham & Company LLC lifted their price objective on shares of Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Leerink Partnrs raised Doximity from a “hold” rating to a “strong-buy” rating in a report on Friday, February 7th. KeyCorp decreased their price objective on Doximity from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Piper Sandler raised Doximity from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $31.00 to $78.00 in a research note on Friday, February 7th. Finally, Leerink Partners upgraded Doximity from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $60.00 to $90.00 in a research report on Friday, February 7th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Doximity currently has an average rating of “Moderate Buy” and an average target price of $64.22.

Doximity Price Performance

Shares of NASDAQ DOCS opened at $75.05 on Monday. The firm has a market capitalization of $14.01 billion, a PE ratio of 75.05, a P/E/G ratio of 4.61 and a beta of 1.39. Doximity has a 1-year low of $22.96 and a 1-year high of $85.21. The business’s fifty day moving average price is $57.03 and its two-hundred day moving average price is $46.83.

Insider Buying and Selling

In other news, Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now directly owns 6,360 shares of the company’s stock, valued at $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 37.40% of the stock is currently owned by insiders.

Institutional Trading of Doximity

Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning increased its position in shares of Doximity by 20.1% in the second quarter. Creative Planning now owns 19,433 shares of the company’s stock worth $544,000 after acquiring an additional 3,251 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Doximity in the 2nd quarter worth approximately $270,000. GAMMA Investing LLC grew its position in Doximity by 40.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,439 shares of the company’s stock worth $63,000 after purchasing an additional 412 shares in the last quarter. Edge Wealth Management LLC acquired a new stake in Doximity during the 3rd quarter valued at $202,000. Finally, nVerses Capital LLC lifted its holdings in shares of Doximity by 67.5% in the third quarter. nVerses Capital LLC now owns 12,900 shares of the company’s stock valued at $562,000 after purchasing an additional 5,200 shares in the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.